For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial.
OBJECTIVE In the 5 - 10 % of diabetic men with type 1 diabetes , erectile dysfunction ( ED ) may be a particularly common and unwanted complication . This is the first study focusing exclusively on the effects of sildenafil in men with type 1 diabetes and ED . RESEARCH DESIGN AND METHODS A total of 188 patients were entered into a double-blind , placebo-controlled , parallel-group , flexible-dose study and were r and omized to receive sildenafil ( 25 - 100 mg ; n = 95 ) or placebo ( n = 93 ) for 12 weeks . Efficacy was evaluated using questions three ( Q3 ; achieving an erection ) and four ( Q4 ; maintaining an erection ) from the International Index of Erectile Function ( IIEF ) , a global efficacy question ( GEQ ; " Did treatment improve your erections ? " ) , and a patient event log of sexual activity . RESULTS Improvements in mean scores from baseline to end-of-treatment for IIEF Q3 ( 35.7 vs. 19.9 % ) and Q4 ( 68.4 vs. 26.5 % ) were significant in patients receiving sildenafil compared with those receiving placebo ( P = 0.0001 ) . Moreover , the percent of improved erections ( GEQ , 66.6 vs. 28.6 % ) and successful intercourse attempts ( 63 vs. 33 % ) was significantly increased with sildenafil compared with placebo . Improvements in sexual function were seen irrespective of the degree of ED severity . Adverse events were generally mild to moderate in severity , with headache ( 20 vs. 8 % ) , flushing ( 18 vs. 3 % ) , and dyspepsia ( 8 vs. 1 % ) reported more often in the sildenafil than in placebo-treated patients . CONCLUSIONS Treatment with sildenafil for ED was effective , result ing in an increased percentage of successful attempts at intercourse , and was well tolerated among men with type 1 diabetes
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .